{
    "clinical_study": {
        "@rank": "35114", 
        "arm_group": {
            "arm_group_label": "the Injection of DanShenDuoFenSuanYan", 
            "description": "Patient who use the Injection of DanShenDuoFenSuanYan"
        }, 
        "brief_summary": {
            "textblock": "Magnesium Lithospermate B, the main constituent of the Injection of DanShenDuoFenSuanYan\n      (the Injection of Depsides Salts From Salvia Miltiorrhiza), is the active ingredient of\n      Salvia Miltiorrhiza. This study record clinical use of The injection of DanShenDuoFenSuanYan\n      in the real world, and observe the adverse drug reactions/ adverse drug events during\n      treatment."
        }, 
        "brief_title": "Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Adverse Drug Reaction", 
        "condition_browse": {
            "mesh_term": "Drug Toxicity"
        }, 
        "detailed_description": {
            "textblock": "As a traditional chinese medicine, the Injection of DanShenDuoFenSuanYan (the Injection of\n      Depsides Salts From Salvia Miltiorrhiza) was approved by State Food and Drug Administration\n      of China in May,2005. This cardiovascular drug is one of the few Traditional Chinese\n      Medicine pharmaceuticals where the active ingredients have been identified in the molecular\n      levels. In its 8 years marketing in China, there is no serious adverse drug reactions.\n\n      In this study, clinical pharmacists in selected hospitals will record the clinical use and\n      the adverse drug reactions/ adverse drug events of this injection.\n\n      This real world study for the Injection of DanShenDuoFenSuanYan with 30400 patients will be\n      conducted from June.2012 to May.2014."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who use the Injection of DanShenDuoFenSuanYan in 30 hospitals in\n             china(including the inpatient and the outpatient(only in some hospitals which can get\n             the information)).\n\n        Exclusion Criteria:\n\n          -  none"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients who use the Injection of DanShenDuoFenSuanYan in 30 hospitals in china(including\n        the inpatient and the outpatient(only in some hospitals which can get the information))"
            }
        }, 
        "enrollment": {
            "#text": "30400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872520", 
            "org_study_id": "PekingUTH-Pharmacy-001"
        }, 
        "intervention_browse": {
            "mesh_term": "Lithospermate B"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "the Injection of DanShenDuoFenSuanYan", 
            "Magnesium Lithospermate B", 
            "Safety", 
            "Real World Study"
        ], 
        "lastchanged_date": "June 5, 2013", 
        "location": {
            "contact": {
                "email": "zhaisuodi@163.com", 
                "last_name": "Suodi ZHAI, B.S.", 
                "phone": "+8615611908515"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100191"
                }, 
                "name": "Peking university third hospital"
            }, 
            "investigator": {
                "last_name": "Suodi ZHAI, B.S.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza): A Real World Study", 
        "overall_contact": {
            "email": "zhaisuodi@163.com", 
            "last_name": "Suodi ZHAI", 
            "phone": "+8615611908515"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: State Administration of Traditional Chinese Medicine of the People's Republic of China", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The adverse reaction rate to the Injection of DanShenDuoFenSuanYan", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "The rare adverse drug reactions to the Injection of DanShenDuoFenSuanYan", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872520"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University Third Hospital", 
            "investigator_full_name": "Suodi ZHAI", 
            "investigator_title": "Suodi ZHAI, Department of Pharmacy, Peking University Third Hospital", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Peking University Third Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Shanghai Greenvalley Pharmaceutical Co., Ltd.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Peking University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Suodi ZHAI", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "2 Weeks", 
        "verification_date": "June 2013"
    }
}